CPL @1096 (98.2%) on 18-jan-2018 [ "drug interactions associated with _" "similar drug called _" "interactions analysis of _" "Drug interactions analysis of _" "new drug called _" "drug interactions between _" "_ is an oral medication" "_ is the second drug" ] using letairis
SEAL @207 (75.0%) on 12-feb-2011 [ 12 ] using letairis
SEAL @178 (75.0%) on 14-dec-2010 [ 12 ] using letairis
MBL @565 (93.8%) on 11-may-2012 [ Promotion of drug:letairis drughassideeffect disease:side_effects ]
CPL @1104 (80.2%) on 18-mar-2018 [ "drug interactions associated with _" "drug called _" "similar drug called _" "interactions analysis of _" "Drug interactions analysis of _" "drug interactions between _" "_ is an oral medication" "drugs , including _" "_ is co-administered with" "_ is the second drug" ] using letairis
NELL has only weak evidence for items listed in grey
CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 for patients taking arg1" "arg2 in patients using arg1" "arg2 and drug interactions does arg1" ] using (letairis, side_effects)
SEAL @524 (75.0%) on 04-mar-2012 [ 12 ] using (letairis, side_effects)
NELL has only weak evidence for items listed in grey
CPL @1094 (87.5%) on 01-jan-2018 [ "arg2 for patients taking arg1" "arg2 in patients using arg1" "arg2 and drug interactions does arg1" ] using (letairis, side_effects)
SEAL @524 (75.0%) on 04-mar-2012 [ 12 ] using (letairis, side_effects)